Phenanthroline

Phenanthroline

SCHEMBL29367277

c1cnc2c(c1)ccc1cccnc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 1.00
CCR8 P51685 5/20 1.00
LMNA P02545 4/20 1.00
CCR5 P51681 3/20 1.00
KDM4E B2RXH2 3/20 1.00
MMP2 P08253 2/20 1.00
TSHR P16473 2/20 1.00
MAPT P10636 2/20 1.00
HTT P42858 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
GMNN O75496 1/20 1.00
TP53 P04637 1/20 1.00
HSP90AA1 P07900 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
MMP9 P14780 1/20 1.00
ALOX15 P16050 1/20 1.00
NFKB1 P19838 1/20 1.00
MMP8 P22894 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthroline SCHEMBL8845760 1.00 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL29354015 1.00 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL8312 1.00 CCR1 (1.00) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL21060516 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL22462277 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL22982126 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL21300488 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL21044608 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL3790396 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E
Phenanthroline SCHEMBL345410 0.97 CCR1 (0.94) CCR1CCR8LMNACCR5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122025517-A Manufacturing method of stable traditional internal liquid filling lithium electrode 桂林优利特医疗电子有限公司 2026-05-12 CN claimed
CN-121085908-B Aromatic amine compound, mixture, organic light-emitting device, and display panel 广州华睿光电材料有限公司 2026-05-12 CN claimed
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO INC (US) 2026-04-09 US claimed
EP-4605407-A2 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS Endevica Bio, Inc. (US) 2025-08-27 EP claimed
CN-120121604-A Rapid detection method for food safety 云南商测质量检验技术服务有限公司 2025-06-10 CN claimed
EP-3720468-B1 TISSUE REPAIR UNIV SUSSEX (GB) 2024-10-30 EP claimed
CN-118831629-A Preparation method and application of Fe-N co-coordination doped porous carbon catalyst 南华大学 2024-10-25 CN claimed
WO-2024086381-A2 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO, INC. (US) 2024-04-25 WO claimed
CN-110041351-B Er (III) luminescent material containing phenanthroline, modified imidazole carboxylic acid and pyridine carboxylic acid mixed ligand and preparation method thereof 洛阳师范学院 2024-04-05 CN claimed
EP-3509993-B1 CALCIUM CARBONATE-CONTAINING COMPOSITE POWDER WITH MICROSTRUCTURED PARTICLES WITH INHIBITING CALCIUM CARBONATE SCHAEFER KALK GMBH & CO KG (DE) 2024-03-06 EP claimed
CN-114342133-A Redox flow battery 新加坡国立大学 2022-04-12 CN claimed
EP-4746862-A2 ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS Aquestive Therapeutics, Inc. (US) 2026-05-27 EP disclosed
CN-122036764-A O-phenanthroline-based double BODIPY fluorescent dye with asymmetric structure, and preparation method and application thereof 齐鲁医药学院 2026-05-15 CN disclosed
CN-122036764-A O-phenanthroline-based double BODIPY fluorescent dye with asymmetric structure, and preparation method and application thereof 齐鲁医药学院 2026-05-15 CN disclosed
CN-122029280-A Oligonucleotide with glycol modification 马萨诸塞大学 2026-05-12 CN disclosed
US-20220072618-A1 LOW-TEMPERATURE CASE HARDENING OF ADDITIVE MANUFACTURED ARTICLES AND MATERIALS AND TARGETED APPLICATION OF SURFACE MODIFICATION SWAGELOK COMPANY 2022-03-10 US disclosed
EP-3475367-B1 PRODUCTION OF CRYSTALLINE CARBON STRUCTURE NETWORKS CARBONX IP 3 B V (NL) 2022-03-09 EP disclosed
EP-3956338-A1 METAL COMPLEXES Merck Patent GmbH (DE) 2022-02-23 EP disclosed
WO-2022031591-A2 OLIGONUCLEOTIDES FOR HTT-1A MODULATION UNIVERSITY OF MASSACHUSETTS (US) 2022-02-10 WO disclosed
CN-109536422-B Aerobic high-density culture method of lactic acid bacteria 广西大学 2022-02-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS MC1R, MC4R, MC5R CCR1 2214/4885CCR8 1955/4885LMNA 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.